Law360 (September 12, 2019, 9:03 PM EDT) -- A Connecticut judge on Wednesday rejected Boehringer Ingelheim Pharmaceuticals' bid to escape its first loss in several bellwether trials over its blood thinner Pradaxa, saying that despite it being "a close call," there was sufficient evidence that additional warnings would have made a difference to a man who suffered internal bleeding on the drug.
In a 65-page ruling, Connecticut Superior Court Judge Carl Schuman denied the motion for judgment or a new trial, upholding the $542,464 verdict a Hartford jury awarded plaintiff Eugene Roberto earlier this year, despite some skepticism about the strength of the evidence supporting Roberto's case.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!